APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Medicine

Nuclear Medicine，or Radiopharmaceuticals， are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Nuclear Medicine，or Radiopharmaceuticals， are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

Selected research

Market Outlook & Growth Opportunities

Global Nuclear Medicine Market Outlook and Growth Opportunities 2026

Report ID 17389500041 January 2026196 pages

Choose your research edition.

Industry ResearchNuclear Medicine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Medicine Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Nuclear Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Medicine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Medicine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Nuclear Medicine，or Radiopharmaceuticals， are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

North America is the largest consumption area, with a consumption market share nearly 50%. Following North America, Europe is the second place consumption region with the consumption market share of about 25%.

Global Nuclear Medicine key manufacturers include GE Healthcare, Bracco Imaging, etc. The global top 2 manufacturers account for over 30 percent of total share.

Read the full market overview

The classification of Nuclear Medicine includes Tc-99, I-123/131, In-111, Xe-133, Th-201 and Ga-67, and the proportion of Tc-99 is about 50%.

Nuclear Medicine is widely used in Diagnostic, Therapeutic. The most proportion of Nuclear Medicine is Diagnostic, and the market share is over 60%.

This report provides an overview of the global Nuclear Medicine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nuclear Medicine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nuclear Medicine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nuclear Medicine market.

Nuclear Medicine Segment by Company

GE Healthcare

Bracco Imaging

Mallinckrodt

Lantheus Medical Imaging

Bayer

Triad Isotopes

Nordion

Jubilant Pharma

Eli Lilly

SIEMENS

China Isotope & Radiation

Dongcheng

Nuclear Medicine Segment by Type

Tc-99

I-123/131

In-111

Xe-133

Th-201

Ga-67

Others

Nuclear Medicine Segment by Application

Diagnostic

Therapeutic

Nuclear Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nuclear Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nuclear Medicine key companies, revenue, market share, and recent developments.

3. To split the Nuclear Medicine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nuclear Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nuclear Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Nuclear Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Medicine industry.

Chapter 3: Detailed analysis of Nuclear Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nuclear Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nuclear Medicine Industry Trends Table 2. Nuclear Medicine Industry Drivers Table 3. Nuclear Medicine Industry Opportunities and Challenges Table 4. Nuclear Medicine Industry Restraints Table 5. Global Nuclear Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nuclear Medicine Revenue Share by Company (2021-2026) Table 7. Global Nuclear Medicine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nuclear Medicine Key Company Manufacturing Base & Headquarters Table 9. Global Nuclear Medicine Company, Product Type & Application Table 10. Global Nuclear Medicine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nuclear Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tc-99 Table 15. Significant Companies of I-123/131 Table 16. Significant Companies of In-111 Table 17. Significant Companies of Xe-133 Table 18. Significant Companies of Th-201 Table 19. Significant Companies of Ga-67 Table 20. Significant Companies of Others Table 21. Global Nuclear Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global Nuclear Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global Nuclear Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global Nuclear Medicine Sales Value Share by Type (2021-2026) Table 25. Global Nuclear Medicine Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Diagnostic Table 27. Significant Companies of Therapeutic Table 28. Global Nuclear Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nuclear Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Nuclear Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Nuclear Medicine Sales Value Share by Application (2021-2026) Table 32. Global Nuclear Medicine Sales Value Share by Application (2027-2032) Table 33. Global Nuclear Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Nuclear Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Nuclear Medicine Sales Value Share by Region (2021-2026) Table 36. Global Nuclear Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Nuclear Medicine Sales Value Share by Region (2027-2032) Table 38. Global Nuclear Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Nuclear Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Nuclear Medicine Sales Value Market Share by Country (2021-2026) Table 41. Global Nuclear Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Nuclear Medicine Sales Value Market Share by Country (2027-2032) Table 43. GE Healthcare Company Information Table 44. GE Healthcare Business Overview Table 45. GE Healthcare Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. GE Healthcare Nuclear Medicine Product Portfolio Table 47. GE Healthcare Recent Development Table 48. Bracco Imaging Company Information Table 49. Bracco Imaging Business Overview Table 50. Bracco Imaging Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Bracco Imaging Nuclear Medicine Product Portfolio Table 52. Bracco Imaging Recent Development Table 53. Mallinckrodt Company Information Table 54. Mallinckrodt Business Overview Table 55. Mallinckrodt Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Mallinckrodt Nuclear Medicine Product Portfolio Table 57. Mallinckrodt Recent Development Table 58. Lantheus Medical Imaging Company Information Table 59. Lantheus Medical Imaging Business Overview Table 60. Lantheus Medical Imaging Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Lantheus Medical Imaging Nuclear Medicine Product Portfolio Table 62. Lantheus Medical Imaging Recent Development Table 63. Bayer Company Information Table 64. Bayer Business Overview Table 65. Bayer Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Bayer Nuclear Medicine Product Portfolio Table 67. Bayer Recent Development Table 68. Triad Isotopes Company Information Table 69. Triad Isotopes Business Overview Table 70. Triad Isotopes Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Triad Isotopes Nuclear Medicine Product Portfolio Table 72. Triad Isotopes Recent Development Table 73. Nordion Company Information Table 74. Nordion Business Overview Table 75. Nordion Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Nordion Nuclear Medicine Product Portfolio Table 77. Nordion Recent Development Table 78. Jubilant Pharma Company Information Table 79. Jubilant Pharma Business Overview Table 80. Jubilant Pharma Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Jubilant Pharma Nuclear Medicine Product Portfolio Table 82. Jubilant Pharma Recent Development Table 83. Eli Lilly Company Information Table 84. Eli Lilly Business Overview Table 85. Eli Lilly Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Eli Lilly Nuclear Medicine Product Portfolio Table 87. Eli Lilly Recent Development Table 88. SIEMENS Company Information Table 89. SIEMENS Business Overview Table 90. SIEMENS Nuclear Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. SIEMENS Nuclear Medicine Product Portfolio Table 92. SIEMENS Recent Development Table 93. China Isotope & Radiation Company Information Table 94. China Isotope & Radiation Business Overview Table 95. China Isotope & Radiation Nuclear Medicine Sales (M Dose), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 96. China Isotope & Radiation Nuclear Medicine Product Portfolio Table 97. China Isotope & Radiation Recent Development Table 98. Dongcheng Company Information Table 99. Dongcheng Business Overview Table 100. Dongcheng Nuclear Medicine Sales (M Dose), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 101. Dongcheng Nuclear Medicine Product Portfolio Table 102. Dongcheng Recent Development Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Nuclear Medicine Product Image Figure 2. Global Nuclear Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Nuclear Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tc-99 Image Figure 8. I-123/131 Image Figure 9. In-111 Image Figure 10. Xe-133 Image Figure 11. Th-201 Image Figure 12. Ga-67 Image Figure 13. Others Image Figure 14. Global Nuclear Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Nuclear Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Nuclear Medicine Sales Value Share by Type (2021-2032) Figure 17. Diagnostic Image Figure 18. Therapeutic Image Figure 19. Global Nuclear Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nuclear Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Nuclear Medicine Sales Value Share by Application (2021-2032) Figure 22. Global Nuclear Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Nuclear Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 25. North America Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 31. South America Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Tc-99
  • I-123/131
  • In-111
  • Xe-133
  • Th-201
  • Ga-67
  • Others
Applications
  • Diagnostic
  • Therapeutic
Companies covered
  • GE Healthcare
  • Bracco Imaging
  • Mallinckrodt
  • Lantheus Medical Imaging
  • Bayer
  • Triad Isotopes
  • Nordion
  • Jubilant Pharma
  • Eli Lilly
  • SIEMENS
  • China Isotope & Radiation
  • Dongcheng

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nuclear Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nuclear Medicine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nuclear Medicine Market Dynamics
  1. 2.1 Nuclear Medicine Industry Trends
  2. 2.2 Nuclear Medicine Industry Drivers
  3. 2.3 Nuclear Medicine Industry Opportunities and Challenges
  4. 2.4 Nuclear Medicine Industry Restraints
3 Nuclear Medicine Market by Company
  1. 3.1 Global Nuclear Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Nuclear Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Nuclear Medicine Company Ranking (2024-2026)
  4. 3.4 Global Nuclear Medicine Company Manufacturing Base and Headquarters
  5. 3.5 Global Nuclear Medicine Company Product Type and Application
  6. 3.6 Global Nuclear Medicine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nuclear Medicine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nuclear Medicine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nuclear Medicine Market by Type
  1. 4.1 Nuclear Medicine Type Introduction
  2. 4.1.1 Tc-99
  3. 4.1.2 I-123/131
  4. 4.1.3 In-111
  5. 4.1.4 Xe-133
  6. 4.1.5 Th-201
  7. 4.1.6 Ga-67
  8. 4.1.7 Others
  9. 4.2 Global Nuclear Medicine Sales Value by Type
  10. 4.2.1 Global Nuclear Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Nuclear Medicine Sales Value by Type (2021-2032)
  12. 4.2.3 Global Nuclear Medicine Sales Value Share by Type (2021-2032)
5 Nuclear Medicine Market by Application
  1. 5.1 Nuclear Medicine Application Introduction
  2. 5.1.1 Diagnostic
  3. 5.1.2 Therapeutic
  4. 5.2 Global Nuclear Medicine Sales Value by Application
  5. 5.2.1 Global Nuclear Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Nuclear Medicine Sales Value by Application (2021-2032)
  7. 5.2.3 Global Nuclear Medicine Sales Value Share by Application (2021-2032)
6 Nuclear Medicine Regional Value Analysis
  1. 6.1 Global Nuclear Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nuclear Medicine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nuclear Medicine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nuclear Medicine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nuclear Medicine Sales Value (2021-2032)
  7. 6.3.2 North America Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nuclear Medicine Sales Value (2021-2032)
  10. 6.4.2 Europe Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nuclear Medicine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nuclear Medicine Sales Value (2021-2032)
  16. 6.6.2 South America Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nuclear Medicine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
7 Nuclear Medicine Country-level Value Analysis
  1. 7.1 Global Nuclear Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nuclear Medicine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nuclear Medicine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nuclear Medicine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nuclear Medicine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nuclear Medicine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nuclear Medicine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nuclear Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nuclear Medicine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nuclear Medicine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nuclear Medicine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nuclear Medicine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nuclear Medicine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nuclear Medicine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nuclear Medicine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nuclear Medicine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nuclear Medicine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nuclear Medicine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nuclear Medicine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nuclear Medicine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nuclear Medicine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nuclear Medicine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nuclear Medicine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nuclear Medicine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nuclear Medicine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nuclear Medicine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nuclear Medicine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nuclear Medicine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nuclear Medicine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nuclear Medicine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nuclear Medicine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nuclear Medicine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GE Healthcare
  2. 8.1.1 GE Healthcare Company Information
  3. 8.1.2 GE Healthcare Business Overview
  4. 8.1.3 GE Healthcare Nuclear Medicine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GE Healthcare Nuclear Medicine Product Portfolio
  6. 8.1.5 GE Healthcare Recent Developments
  7. 8.2 Bracco Imaging
  8. 8.2.1 Bracco Imaging Company Information
  9. 8.2.2 Bracco Imaging Business Overview
  10. 8.2.3 Bracco Imaging Nuclear Medicine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bracco Imaging Nuclear Medicine Product Portfolio
  12. 8.2.5 Bracco Imaging Recent Developments
  13. 8.3 Mallinckrodt
  14. 8.3.1 Mallinckrodt Company Information
  15. 8.3.2 Mallinckrodt Business Overview
  16. 8.3.3 Mallinckrodt Nuclear Medicine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Nuclear Medicine Product Portfolio
  18. 8.3.5 Mallinckrodt Recent Developments
  19. 8.4 Lantheus Medical Imaging
  20. 8.4.1 Lantheus Medical Imaging Company Information
  21. 8.4.2 Lantheus Medical Imaging Business Overview
  22. 8.4.3 Lantheus Medical Imaging Nuclear Medicine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lantheus Medical Imaging Nuclear Medicine Product Portfolio
  24. 8.4.5 Lantheus Medical Imaging Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Nuclear Medicine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Nuclear Medicine Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Triad Isotopes
  32. 8.6.1 Triad Isotopes Company Information
  33. 8.6.2 Triad Isotopes Business Overview
  34. 8.6.3 Triad Isotopes Nuclear Medicine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Triad Isotopes Nuclear Medicine Product Portfolio
  36. 8.6.5 Triad Isotopes Recent Developments
  37. 8.7 Nordion
  38. 8.7.1 Nordion Company Information
  39. 8.7.2 Nordion Business Overview
  40. 8.7.3 Nordion Nuclear Medicine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Nordion Nuclear Medicine Product Portfolio
  42. 8.7.5 Nordion Recent Developments
  43. 8.8 Jubilant Pharma
  44. 8.8.1 Jubilant Pharma Company Information
  45. 8.8.2 Jubilant Pharma Business Overview
  46. 8.8.3 Jubilant Pharma Nuclear Medicine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Jubilant Pharma Nuclear Medicine Product Portfolio
  48. 8.8.5 Jubilant Pharma Recent Developments
  49. 8.9 Eli Lilly
  50. 8.9.1 Eli Lilly Company Information
  51. 8.9.2 Eli Lilly Business Overview
  52. 8.9.3 Eli Lilly Nuclear Medicine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly Nuclear Medicine Product Portfolio
  54. 8.9.5 Eli Lilly Recent Developments
  55. 8.10 SIEMENS
  56. 8.10.1 SIEMENS Company Information
  57. 8.10.2 SIEMENS Business Overview
  58. 8.10.3 SIEMENS Nuclear Medicine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 SIEMENS Nuclear Medicine Product Portfolio
  60. 8.10.5 SIEMENS Recent Developments
  61. 8.11 China Isotope & Radiation
  62. 8.11.1 China Isotope & Radiation Company Information
  63. 8.11.2 China Isotope & Radiation Business Overview
  64. 8.11.3 China Isotope & Radiation Nuclear Medicine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 China Isotope & Radiation Nuclear Medicine Product Portfolio
  66. 8.11.5 China Isotope & Radiation Recent Developments
  67. 8.12 Dongcheng
  68. 8.12.1 Dongcheng Company Information
  69. 8.12.2 Dongcheng Business Overview
  70. 8.12.3 Dongcheng Nuclear Medicine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Dongcheng Nuclear Medicine Product Portfolio
  72. 8.12.5 Dongcheng Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst